Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Pharmaceuticals Secures USD $1.9 Million Sales Contract for SmoothX 2% (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Baxter International Inc BAX

Healthcare Medical Devices
Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. Its Healthcare Systems and Technologies segment includes... see more

Recent & Breaking News (NYSE:BAX)

Baxter Receives FDA Approval for PHOXILLUM Solution for Electrolyte Management During Continuous Renal Replacement Therapy

Business Wire January 20, 2015

Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium

GlobeNewswire January 20, 2015

Palmetto Health in Columbia, South Carolina, Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service

Business Wire January 15, 2015

Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment for Von Willebrand Disease

Business Wire December 22, 2014

Baxter to Present at 33rd Annual J.P. Morgan Healthcare Conference

Business Wire December 18, 2014

Baxter International Fourth Quarter 2014 Financial Results Conference Call

Business Wire December 17, 2014

Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics

Business Wire December 15, 2014

Baxter Announces Filing of Form 10 Registration Statement in Connection with Planned Spin off of Biopharmaceuticals Business

Business Wire December 10, 2014

Baxter's Culture of Community Engagement and Inclusion Recognized by Leading Organizations

Business Wire December 9, 2014

Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research

GlobeNewswire December 4, 2014

Baxter Submits Application for U.S. FDA Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A

Business Wire December 1, 2014

Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer

GlobeNewswire November 19, 2014

Baxter to Present at the 26th Annual Piper Jaffray Healthcare Conference

Business Wire November 13, 2014

Baxter Declares Quarterly Dividend

Business Wire November 11, 2014

Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer

GlobeNewswire November 6, 2014

Baxter to Present at the Stifel 2014 Healthcare Conference

Business Wire November 5, 2014

Life-Science New Build Report: 200 New North American Sites in Planning Represent Potential $15 Billion Investment, an Industrial Info News Alert

Marketwired November 4, 2014

Baxter's Investigational 20% Subcutaneous Immunoglobulin Treatment Meets Efficacy and Tolerability Endpoints in Phase 2/3 Study

Business Wire October 30, 2014

Pharmaceutical-Biotech Industry to Wrap Up Year With $4.5 Billion Investment in Fourth-Quarter 2014 Project Starts, an Industrial Info News Alert

Marketwired October 30, 2014

FDA Approves Baxter's OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired Hemophilia A

Business Wire October 24, 2014